Targeting dendritic cells: a promising strategy to improve vaccine effectiveness

Christophe Macri; Claire Dumont; Angus Pr Johnston; Justine D Mintern

doi:10.1038/cti.2016.6

Targeting dendritic cells: a promising strategy to improve vaccine effectiveness

Clin Transl Immunology. 2016 Mar 18;5(3):e66. doi: 10.1038/cti.2016.6. eCollection 2016 Mar.

Authors

Christophe Macri¹, Claire Dumont², Angus Pr Johnston³, Justine D Mintern²

Affiliations

¹ Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University , Clayton, Victoria, Australia.
² Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne , Parkville, Victoria, Australia.
³ Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, Parkville, Victoria, Australia.

Abstract

Dendritic cell (DC) targeting is a novel strategy to enhance vaccination efficacy. This approach is based on the in situ delivery of antigen via antibodies that are specific for endocytic receptors expressed at the surface of DCs. Here we review the complexity of the DC subsets and the antigen presentation pathways that need to be considered in the settings of DC targeting. We also summarize current knowledge about antigen delivery to DCs via DEC-205, Clec9A and Clec12A, receptor targets that strongly enhance cellular and humoral immune responses. Finally, we discuss the intracellular trafficking criteria of the targeted receptors that may impact their effectiveness as DC targets.

Publication types

Review